Yocca Frank 4

What Happened
Frank Yocca, Chief Scientific Officer of BioXcel Therapeutics (BTAI), reported the vesting/conversion of 9,000 restricted stock units (RSUs) on May 1, 2026. The Form 4 shows an acquisition entry for 9,000 shares via exercise/conversion (transaction code M) and a matching disposition of 9,000 shares reported at $0.00. No cash proceeds or exercise price are reported.

Key Details

• Transaction date: May 1, 2026 (reported on Form 4 filed May 7, 2026).
• Prices/values shown: Acquisition listed as N/A; disposition listed at $0.00 (no cash proceeds reported).
• Shares owned after transaction: Not disclosed in this filing.
• Footnotes: F1 — each RSU converts to one share of common stock; F2 — these 9,000 RSUs were granted on Aug 1, 2025 and vested 100% on or within 30 days of nine months from the grant date (effectively May 1, 2026).
• Filing timeliness: The Form 4 was filed six days after the transaction date, outside the typical two-business-day reporting window.

Context
This was a derivative conversion of RSUs rather than an open-market purchase or sale. A disposition reported at $0.00 typically indicates a conversion/settlement (for example, issuance and immediate withholding/cancellation) rather than a cash sale; the filing does not specify the reason. No explicit tax-withholding or sale-for-cash details are provided, and the filing does not state resulting share ownership.